Document is current
Any future updates will be listed below
-
Authors
Schulmeyer, Carla
Fasching, Peter A.
Beckmann, Matthias W.
Häberle, Lothar
Golcher, Henriette
Goebell, Peter J.
Pöschke, Patrik
Emons, Julius
-
Funding
Funding for this research was provided by:
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 30 December 2024
Accepted: 21 February 2025
First Online: 2 April 2025
Declarations
:
: P.A.F. reports grants from BioNTech and Cepheid, personal fees from Novartis, Pfizer, Daiichi Sankyo, AstraZeneca, Eisai, MSD, Lilly, Pierre Fabre, SeaGen, Roche, Hexal, Agendia, and Gilead. J.E. reports honoraria from Eisai, Novartis, and Pfizer. P.J.G. is a trialist for Cepheid, California, USA. All other authors have declared that they do not have any conflicts of interest.
: The study was approved by the Ethics Committee at Erlangen University Hospital (no. 175_13B) and was conducted in accordance with the ethical principles set out in the Declaration of Helsinki.
: Informed consent was obtained from all of the patients who participated in the study.
